Completed PHASE1 INTERVENTIONAL 1-arm NCT04812691

CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma

CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions Diffuse Large B Cell Lymphoma

Interventions JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

Updated 5 times since 2021 Last updated: Nov 21, 2023 Started: Jul 10, 2020 Primary completion: Jun 30, 2021 Completion: Apr 25, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Diffuse Large B Cell Lymphoma, this trial is completed. The trial is conducted by Shanghai Ming Ju Biotechnology Co., Ltd. and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
May 2023 — Dec 2023 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Apr 2021 — May 2023 [monthly]

Recruiting PHASE1

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Ming Ju Biotechnology Co., Ltd.

Data source: Shanghai Ming Ju Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China
• Shanghai, China